Shanyu pill: It consists of Chinese yam, Atractylodes macrocephala, and ginseng.
Placebo: It consists of corn starch and dextrin
Study summary
Sarcopenia is an age-related condition characterized by progressive loss of muscle mass, muscle strength, and physical function. It may also be associated with impaired cognitive function. Effective treatment options for sarcopenia remain limited.
This multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the effects of Shanyu Pill in older adults with sarcopenia. A total of 192 participants are randomly assigned in a 1:1 ratio to receive either Shanyu Pill or placebo for 24 weeks. A long-term follow-up assessment is scheduled 2 years after completion of the 24-week intervention.
The primary outcome is the change in appendicular skeletal muscle mass index (ASMI) from baseline to week 24. Other assessments include muscle strength, physical performance, cognitive function, and traditional Chinese medicine syndrome severity assessed using the Spleen Qi Deficiency Syndrome Score. Musculoskeletal ultrasound, functional near-infrared spectroscopy, gut microbiota analysis, and untargeted metabolomics are also used in subsets of participants to explore potential mechanisms associated with the effects of Shanyu Pill, including possible interactions within the gut-muscle-brain axis.
Eligibility
Sex
ALL
Min age
60 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age 60-85 years; meeting the Asian Working Group for Sarcopenia (AWGS) diagnostic criteria for sarcopenia and the traditional Chinese medicine diagnostic criteria for spleen qi deficiency syndrome.
2. Able to understand and cooperate with study procedures and voluntarily provide written informed consent.
Exclusion Criteria:
1. Severe neurological or musculoskeletal disorders that may affect motor function, including severe osteoporosis or severe osteoarthritis.
2. Severe cardiovascular, pulmonary, or psychiatric disorders; uncontrolled endocrine or metabolic diseases; or severe hepatic or renal dysfunction, including cirrhosis, renal failure, or dialysis.
3. Inability to communicate effectively with the investigators because of speech impairment or uncorrected hearing impairment.
4. Severe cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score \<24, resulting in an inability to understand or complete the study questionnaires and assessments.
5. Use of growth hormone, estrogen, progesterone, testosterone, or related hormonal supplements within the previous 3 months, or presence of severe nutritional deficiency.
6. Participation in another clinical trial or a clinical trial involving traditional Chinese medicine supplements within the previous 3 months.
Primary outcome measure(s)
Change From Baseline in Appendicular Skeletal Muscle Mass Index (ASMI) — Baseline, Week 12, Week 24, and 2 years after completion of the 24-week intervention Appendicular skeletal muscle mass (ASM) is assessed using dual-energy X-ray absorptiometry (DXA). ASM is calculated as the sum of lean soft tissue mass of the arms and legs. Appendicular skeletal muscle mass index (ASMI) is calculated as ASM divided by height squared (kg/m²). Changes in ASMI from baseline are assessed at week 12, week 24, and 2 years after completion of the 24-week intervention.The primary efficacy endpoint is the change in ASMI from baseline to week 24.
Trial sites (3)
Facility
City
Region
Status
Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine
Fuzhou
Fujian
The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine
Fuzhou
Fujian
The Sixth Affiliated Hospital, Sun Yat-sen University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.